During a World Health Care Congress 2019 panel discussion on unlocking innovation in value-based care, panel members offered a comprehensive look at what’s driving this shift toward value-based care, what works and what doesn’t, and where consolidation fits into the mix.
Basit Chaudhry, MD, PhD, founder of Tuple Health, explains why it's important to evaluate the adequacy of the novel therapy adjustment under the Oncology Care Model (OCM).
As Howard A. "Skip" Burris, III, MD, FACP, FASCO, president, clinical operations, and chief medical officer of Sarah Cannon Research Institute, prepares to become the president of the American Society of Clinical Oncology (ASCO) in June, he discusses what his focus will be.
During a session at the National Association of Accountable Care Organizations (ACOs), top performing ACOs shared lessons learned and best practices for ensuring compliance with quality measures while keeping the patient at the forefront.
In addition to helping make treatment decisions, COTA's real-world data platform can help oncologists understand and identify areas where there is treatment variability and help them work to contain cost in the long run, explained C.K. Wang, MD, senior medical director, COTA.
Technology interventions have to be targeted at the right patients and be properly explained to them, explained Joann Sciandra, RN, BSN, CCM, associate vice president of healthcare management, Geisinger Health System.
The new primary care models from HHS will provide greater flexibility to practices that want to participate and deliver care in a different way to reduce hospitalizations, said Travis Broome, vice president of policy at Aledade.
During a session at the National Association of Accountable Care Organizations (ACOs), panelists offered perspectives on how ACOs can successfully address social and behavioral needs of their patients.
Creating a value-based care system means upending the current one and providing more models to encourage providers to take on risk.
Clinical trial criteria is really about patient safety and making sure participating patients don't experience undue risks, explained Katie Goodman, RN, BSN, CCRP, director of clinical research, Florida Cancer Specialists & Research Institute.
Crescent Moore, PharmD, PhD, BCPS, senior consultant, BluePeak Advisors, discusses how CMS is planning on implementing care coordination programs in Medicare.
Early education and communication are needed for successful uptake of biosimilars, explained Sonia T. Oskouei, PharmD, director, Pharmacy Program Development for Biosimilars, Premier Inc.
Lee Schwartzberg, MD, FACP, executive director, West Cancer Center, discusses his thoughts on calls for every person diagnosed with breast cancer to receive a multigene panel.
While the physician shortage is having an impact in rural areas, the impact of physician burnout is happening across the board, said Jeff Patton, MD, chief executive officer of Tennessee Oncology.
Using rapid-cycle analytics of real-world evidence, we can get patients on the most appropriate medications and also implement medication adherence interventions, explained Sebastian Schneeweiss, MD, ScD, professor of medicine and epidemiology, Harvard Medical School and Brigham and Women's Hospital, and co-founder of Aetion.
Part of the challenge has been the distribution of cost structure under the Oncology Care Model (OCM), particularly with respect to pharmaceuticals, explained Basit Chaudhry, MD, PhD, founder of Tuple Health.
Multimorbidity in older patients creates a challenge because you're dealing with multiple diseases and multiple medications, explained Michael Steinman, MD, professor of medicine, University of California, San Diego.
Real-world data offers a glimpse into what happens to patients treated by real-world doctors under real-world circumstances, explained C.K. Wang, MD, senior medical director, COTA.
In a discussion at the 2019 Spring Session of the Florida Society of Clinical Oncology, speakers provided updates to the treatment landscape for lung cancer and presented a case study from the clinic.
Rick McDonough, MD, president of the Florida Society of Clinical Oncology, explains why right now is a great time to get into the oncology field.
Michael Kolodziej, MD, vice president and chief innovation officer at ADVI Health, discusses the importance of oncology practices participating in alternative payment models (APMs).
To begin a session on the reimbursement of genetic testing during the Florida Society of Clinical Oncology’s annual meeting in Kissimmee, Florida, incoming president Luis E. Raez, MD, put things in perspective: “I’ve been practicing for more than 30 years, and it used to be that when you would explain a treatment plan to a patient, they would ask if they’re going to respond to it and you would have to say ‘I don’t know.’ Now, with genetic testing, hopefully you can say ‘yes.’”
CMS has given plan sponsors the flexibility to choose which drug therapy categories they’d like to administer the Part B step on, explained Crescent Moore, PharmD, PhD, BCPS, senior consultant, BluePeak Advisors,
Making lifesaving but costly cancer therapies available to patients requires collaboration across the healthcare system, agreed a panel of stakeholders at the Business of Oncology Summit hosted by the Florida Society of Clinical Oncology.
Thomas Marsland, MD, talks about financial toxicity and the effect it has on patients.
Luis E. Raez, MD, incoming president of the Florida Society of Clinical Oncology, provides an overview of his goals for his upcoming term.
In a panel discussion during the Business of Oncology Summit hosted by the Florida Society of Clinical Oncology, survivors and caregivers described how their cancer journeys were affected by financial toxicity.
The treatment of lung cancer with personalized medicine has come a long way in recent decades, but still more achievements remain to be seen, said Bruce Johnson, MD, FASCO, immediate past president of the American Society of Clinical Oncology, during his keynote speech opening the Business of Oncology Summit hosted by the Florida Society of Clinical Oncology in Kissimmee, Florida.
"By being a part of this membership, you get access to education, information, resources, [and] materials that are hopefully going to be helpful in the care of cancer patients," said Rick McDonough, MD, president of the Florida Society of Clinical Oncology (FLASCO).
The breast cancer community is very excited about the approval of atezolimuab for the treatment of triple-negative breast cancer, explained Lee Schwartzberg, MD, FACP, executive director, West Cancer Center.